LABORATORY AND CLINICAL STUDIES WITH CEFOXITIN

• Published in: CHEMOTHERAPY Vol. 26; no. Supplement1; pp. 528 - 535
• Main Authors: IKI, YOSHIO, OGAWA, HIDEYA
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 31.03.1978
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.26.Supplement1_528

1) Minimum inhibitory concetrations (MIC) were measured against Gram-negative rods isolated from the urinary tract. The results were as follows: E. coli; 1.6-6.3μg/ml, Klebsiella and Proteus; 1.6-6.3μg/ml against almost all strains, Enterobacter, Serratia and Pseudomonas; ≥100μg/ml. A favorable result was obtained between correlation of MICs and disc sensitivity. 2) Concentrations of cefoxitin in serum and urine and recovery in urine were measured in 2 patients following bolus intravenous injection of 1 g and 60-minute drip infusion of 2 g in 250 ml of saline. 3) Cefoxitin was given to patients 2 g b.i.d. for 5 to 7 days by drip infusion. Patients with acute UTI as well as prophylaxis cases responded well; 5 out of 6 cases were judged effective. Eight cases were judged effective out of 12 patients, including chronic UTI, in total. 4) Bacteriologically, a favorable eradicative effect was seen in E. coli infections. 5) No abnormal fluctuations of values were noted in hematology and blood chemistry. Subjective side effects were not observed either.